Antonio Seguro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Seguro has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
A.L. de Souza
Intensive Care Unit, Emílio Ribas Institute of Infectology, University of São Paulo School of Medicine São Paulo, Brazil
1 shared publication- Adriana Castello Costa Girardi
Universidade de São Paulo
1 shared publication - Daniele Canale
Laboratorio de Investigacao Medica 12 (LIM12), Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
1 shared publication - Erika Fernandes Jesus
Departamento de Cardiopneumologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil
1 shared publication - Flávia Letícia Martins
Universidade de São Paulo
1 shared publication - James A. McCormick
Oregon Health and Science University
1 shared publication
Latest Publications
- 2 April 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1689-1701
SGLT2 Inhibitors Blunt Kidney Magnesium Wasting in Acute Cisplatin-Induced Hypomagnesemia with Effects on the Thick Ascending Limb and Distal Convoluted Tubule
Key Points: Sodium-glucose cotransporter 2 inhibitors restored magnesium serum levels in cisplatin-treated rats. Empagliflozin reversed cisplatin-induced Na + -K + -Cl − cotransporter 2 inhibition and claudin-16 downregulation in the thick ascending limb. Empagliflozin mitigated distal convoluted tubule area reduction, normalized NaCl cotransporter function, and restored transient receptor potential melastatin 6 expression. Background: Cisplatin, a chemotherapeutic agent, induces kidney magnesium wasting and hypomagnesemia. Recent studies suggest that sodium-glucose cotransporter 2 inhibitors elevate serum magnesium concentration in patients with or without diabetes. We hypothesized that the sodium-glucose cotransporter 2 inhibitor empagliflozin attenuates acute cisplatin-induced hypomagnesemia by acting on the thick ascending limb (TAL) and distal convoluted tubule (DCT), key sites of magnesium reabsorption. Methods: Adult male Wistar rats received weekly treatments of cisplatin (2.5 mg/kg) or saline (vehicle) for 5 weeks. After 3 weeks, rats were randomized to receive empagliflozin (10 mg/kg per day) or water (vehicle) for the next 15 days. Results: Cisplatin-treated rats developed significant hypomagnesemia with increased fractional excretion of magnesium. Empagliflozin treatment reduced fractional excretion of magnesium and restored serum magnesium levels. In the TAL, cisplatin-treated rats had higher Na + -K + -Cl − cotransporter 2 (NKCC2) abundance but lower phosphorylated NKCC2 and claudin-16 levels than empagliflozin-treated cisplatin rats, whose protein levels were similar to controls. By contrast, claudin-19 abundance in the TAL was higher in cisplatin-treated rats than in controls and unaffected by empagliflozin treatment. In the DCT, cisplatin-treated rats displayed reduced abundance of the NaCl cotransporter (NCC), the magnesium channel transient receptor potential melastatin 6, and NCC phosphorylation, all of which were rescued by empagliflozin. Unexpectedly, cisplatin-treated rats exhibited higher mRNA expression and protein abundance of TRPM7 compared with empagliflozin-treated cisplatin rats, whose levels were similar to controls. Diuretic challenge tests with furosemide or hydrochlorothiazide confirmed reduced NKCC2 and NCC activity in cisplatin-treated rats. However, the natriuretic response to furosemide or hydrochlorothiazide did not differ between control and empagliflozin-treated cisplatin rats. Immunohistochemistry suggested that empagliflozin reversed cisplatin-induced DCT remodeling. Conclusions: Empagliflozin reduces kidney magnesium wasting and restores serum magnesium in cisplatin-treated rats, likely through reversing NKCC2 inhibition and claudin-16 downregulation in the TAL while normalizing NCC function and restoring transient receptor potential melastatin 6 expression in the DCT.
- 2 April 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1689-1701
SGLT2 Inhibitors Blunt Kidney Magnesium Wasting in Acute Cisplatin-Induced Hypomagnesemia with Effects on the Thick Ascending Limb and Distal Convoluted Tubule
Key Points: Sodium-glucose cotransporter 2 inhibitors restored magnesium serum levels in cisplatin-treated rats. Empagliflozin reversed cisplatin-induced Na + -K + -Cl − cotransporter 2 inhibition and claudin-16 downregulation in the thick ascending limb. Empagliflozin mitigated distal convoluted tubule area reduction, normalized NaCl cotransporter function, and restored transient receptor potential melastatin 6 expression. Background: Cisplatin, a chemotherapeutic agent, induces kidney magnesium wasting and hypomagnesemia. Recent studies suggest that sodium-glucose cotransporter 2 inhibitors elevate serum magnesium concentration in patients with or without diabetes. We hypothesized that the sodium-glucose cotransporter 2 inhibitor empagliflozin attenuates acute cisplatin-induced hypomagnesemia by acting on the thick ascending limb (TAL) and distal convoluted tubule (DCT), key sites of magnesium reabsorption. Methods: Adult male Wistar rats received weekly treatments of cisplatin (2.5 mg/kg) or saline (vehicle) for 5 weeks. After 3 weeks, rats were randomized to receive empagliflozin (10 mg/kg per day) or water (vehicle) for the next 15 days. Results: Cisplatin-treated rats developed significant hypomagnesemia with increased fractional excretion of magnesium. Empagliflozin treatment reduced fractional excretion of magnesium and restored serum magnesium levels. In the TAL, cisplatin-treated rats had higher Na + -K + -Cl − cotransporter 2 (NKCC2) abundance but lower phosphorylated NKCC2 and claudin-16 levels than empagliflozin-treated cisplatin rats, whose protein levels were similar to controls. By contrast, claudin-19 abundance in the TAL was higher in cisplatin-treated rats than in controls and unaffected by empagliflozin treatment. In the DCT, cisplatin-treated rats displayed reduced abundance of the NaCl cotransporter (NCC), the magnesium channel transient receptor potential melastatin 6, and NCC phosphorylation, all of which were rescued by empagliflozin. Unexpectedly, cisplatin-treated rats exhibited higher mRNA expression and protein abundance of TRPM7 compared with empagliflozin-treated cisplatin rats, whose levels were similar to controls. Diuretic challenge tests with furosemide or hydrochlorothiazide confirmed reduced NKCC2 and NCC activity in cisplatin-treated rats. However, the natriuretic response to furosemide or hydrochlorothiazide did not differ between control and empagliflozin-treated cisplatin rats. Immunohistochemistry suggested that empagliflozin reversed cisplatin-induced DCT remodeling. Conclusions: Empagliflozin reduces kidney magnesium wasting and restores serum magnesium in cisplatin-treated rats, likely through reversing NKCC2 inhibition and claudin-16 downregulation in the TAL while normalizing NCC function and restoring transient receptor potential melastatin 6 expression in the DCT.
- 29 November 2019
- Published by H1 Connect
Faculty Opinions recommendation of Pioglitazone attenuates kidney injury in an experimental model of gentamicin-induced nephrotoxicity in rats.
In this very interesting article, the authors demonstrated that pioglitazone, a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, attenuates acute kidney injury induced by gentamicin in rats by anti-inflammatory and antoxidant mechanisms. Rosiglitazone, another PPAR-γ receptor agonist, increases the expression of tubular transporters, such as sodium/hydrogen exchanger 3, sodium-phosphate cotransporter subtype IIa, NKCC2 in the thick ascending limb of Henle and also the expression of aquaporin 2 in collecting duct, Since gentamicin decreases the expression of these transporters, it would be interesting to perform experiments to evaluate whether the protective effect of piogliazone in this model of acute kidney injury (AKI) is also due to an upregulation of these tubular transporters.
- 29 November 2019
- Published by H1 Connect
Faculty Opinions recommendation of Pioglitazone attenuates kidney injury in an experimental model of gentamicin-induced nephrotoxicity in rats.
In this very interesting article, the authors demonstrated that pioglitazone, a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, attenuates acute kidney injury induced by gentamicin in rats by anti-inflammatory and antoxidant mechanisms. Rosiglitazone, another PPAR-γ receptor agonist, increases the expression of tubular transporters, such as sodium/hydrogen exchanger 3, sodium-phosphate cotransporter subtype IIa, NKCC2 in the thick ascending limb of Henle and also the expression of aquaporin 2 in collecting duct, Since gentamicin decreases the expression of these transporters, it would be interesting to perform experiments to evaluate whether the protective effect of piogliazone in this model of acute kidney injury (AKI) is also due to an upregulation of these tubular transporters.
- 26 June 2019
- Published by H1 Connect
Faculty Opinions recommendation of Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking.
In this interesting experimental study, the authors demonstrated by in vitro and in vivo methods that fluconazole increased aquaporin-2 (AQP2) plasma membrane localization in principal cells of collecting ducts independently of arginine vasopressin. This antifungal in mice reduced urine output even in animals treated with tolvaptan. This drug or others with similar chemical structure may be a potential therapy for nephrogenic diabetes insipidus. However, it is important to emphasize that the chronic use of this drug may induce hyponatremia in patients who maintain excessive water intake. It would be interesting to monitor sodium plasma levels of patients with fungal infections treated with fluconazole.
- 26 June 2019
- Published by H1 Connect
Faculty Opinions recommendation of Fluconazole Increases Osmotic Water Transport in Renal Collecting Duct through Effects on Aquaporin-2 Trafficking.
In this interesting experimental study, the authors demonstrated by in vitro and in vivo methods that fluconazole increased aquaporin-2 (AQP2) plasma membrane localization in principal cells of collecting ducts independently of arginine vasopressin. This antifungal in mice reduced urine output even in animals treated with tolvaptan. This drug or others with similar chemical structure may be a potential therapy for nephrogenic diabetes insipidus. However, it is important to emphasize that the chronic use of this drug may induce hyponatremia in patients who maintain excessive water intake. It would be interesting to monitor sodium plasma levels of patients with fungal infections treated with fluconazole.
- 28 December 2018
- Published by H1 Connect
Faculty Opinions recommendation of Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis.
This is an interesting study. The authors retrospectively assessed 182 patients with acute interstitial nephritis proven by renal biopsy. According to the results, 27% were caused by the use of non-steroidal anti-inflammatory drugs. In 30%, no drug was identified. Possible drugs causing the disorder were withdrawn in an average time of 11 days. All patients with acute renal injury were treated with corticosteroids. Withdrawal of the drug and early treatment led to a high rate of recovery of renal function. Treatment with corticosteroids at high doses for 3 weeks or prolonged for more than 8 weeks did not result in a greater recovery of renal function. These results highlight the importance in medical practice of an early diagnosis and treatment of acute interstitial nephritis induced by drugs.
- 28 December 2018
- Published by H1 Connect
Faculty Opinions recommendation of Duration of Treatment with Corticosteroids and Recovery of Kidney Function in Acute Interstitial Nephritis.
This is an interesting study. The authors retrospectively assessed 182 patients with acute interstitial nephritis proven by renal biopsy. According to the results, 27% were caused by the use of non-steroidal anti-inflammatory drugs. In 30%, no drug was identified. Possible drugs causing the disorder were withdrawn in an average time of 11 days. All patients with acute renal injury were treated with corticosteroids. Withdrawal of the drug and early treatment led to a high rate of recovery of renal function. Treatment with corticosteroids at high doses for 3 weeks or prolonged for more than 8 weeks did not result in a greater recovery of renal function. These results highlight the importance in medical practice of an early diagnosis and treatment of acute interstitial nephritis induced by drugs.
- 1 January 2018
- Published by Elsevier
- p. 207-217
Vitamin D, Oxidative Stress, and the Antiretroviral Tenofovir
- 1 January 2018
- Published by Elsevier
- p. 207-217
Vitamin D, Oxidative Stress, and the Antiretroviral Tenofovir
- 23 June 2017
- Published by H1 Connect
Faculty Opinions recommendation of Kidney transplantation from donors with rhabdomyolysis and acute renal failure.
In this interesting study, the authors evaluated 30 kidney transplantations from 15 deceased donors with acute kidney injury (AKI) due to severe rhabdomyolysis and compared this group with 90 renal grafts from standard-criteria donors. Two years after transplantation the estimated glomerular filtration rate was similar between the two groups. The conclusion was that kidneys from donors with AKI due to rhabdomyolysis can achieve excellent graft function. A recent experimental study of our group in a rat model of rhabdomyolysis-associated AKI induced by glycerol injection demonstrated that allopurinol attenuates renal dysfunction in these animals by reducing oxidative stress, apoptosis and inflammation {1}. Since the 30 kidneys of donors were perfused with Belzer's solution, which contains allopurinol, this substance may have contributed to the graft function achieved in this group. The present study demonstrated that kidneys from deceased donors with AKI due to rhabdomyolysis should not be excluded for transplantation.
- 23 June 2017
- Published by H1 Connect
Faculty Opinions recommendation of Kidney transplantation from donors with rhabdomyolysis and acute renal failure.
In this interesting study, the authors evaluated 30 kidney transplantations from 15 deceased donors with acute kidney injury (AKI) due to severe rhabdomyolysis and compared this group with 90 renal grafts from standard-criteria donors. Two years after transplantation the estimated glomerular filtration rate was similar between the two groups. The conclusion was that kidneys from donors with AKI due to rhabdomyolysis can achieve excellent graft function. A recent experimental study of our group in a rat model of rhabdomyolysis-associated AKI induced by glycerol injection demonstrated that allopurinol attenuates renal dysfunction in these animals by reducing oxidative stress, apoptosis and inflammation {1}. Since the 30 kidneys of donors were perfused with Belzer's solution, which contains allopurinol, this substance may have contributed to the graft function achieved in this group. The present study demonstrated that kidneys from deceased donors with AKI due to rhabdomyolysis should not be excluded for transplantation.
- 24 February 2017
- Published by H1 Connect
Faculty Opinions recommendation of Aliskiren Increases Aquaporin-2 Expression and Attenuates Lithium-induced Nephrogenic Diabetes Insipidus.
In this interesting experimental study the authors investigated in mice the effect of the direct renin inhibitor aliskiren on aquaporin expression in the collecting duct. In mice with nephrogenic diabetes insipidus induced by lithium, aliskiren decreased urine volume and increased urine osmolality by increasing aquaporin 2 (AQP2) expression in kidney inner medulla. This renin inhibitor increased cAMP levels when compared to controls and reversed the decreased cAMP induced by lithium. In suspension of inner medullary collecting cells, aliskiren increased AQP2 and pS256-AQP2 protein, which was inhibited by adenylyl cyclase inhibitor MDL-12330A and PKA inhibitor H89 but not by the V2R antagonist.
- 24 February 2017
- Published by H1 Connect
Faculty Opinions recommendation of Aliskiren Increases Aquaporin-2 Expression and Attenuates Lithium-induced Nephrogenic Diabetes Insipidus.
In this interesting experimental study the authors investigated in mice the effect of the direct renin inhibitor aliskiren on aquaporin expression in the collecting duct. In mice with nephrogenic diabetes insipidus induced by lithium, aliskiren decreased urine volume and increased urine osmolality by increasing aquaporin 2 (AQP2) expression in kidney inner medulla. This renin inhibitor increased cAMP levels when compared to controls and reversed the decreased cAMP induced by lithium. In suspension of inner medullary collecting cells, aliskiren increased AQP2 and pS256-AQP2 protein, which was inhibited by adenylyl cyclase inhibitor MDL-12330A and PKA inhibitor H89 but not by the V2R antagonist.
- 5 October 2016
- Published by H1 Connect
Faculty Opinions recommendation of HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.
In this interesting large cohort study, the authors measured urine α1-microglobulin (A1M) in men with HIV infection and tenofovir disoproxil fumarate (TDF) exposure, mainly with normal kidney function. The results demonstrated that HIV-infected patients presented higher urine A1M levels when compared with HIV-uninfected patients. In HIV-infected patients, higher levels of urine A1M were associated with cumulative TDF use. What was also interesting was the fact that TDF discontinuation was associated with a decrease in A1M levels. These data indicate that urine A1M may be a biomarker of TDF tubular injury. A study from our laboratory {1} demonstrated in rats that low doses of TDF induced tubular nephrotoxicity prior to a decrease in glomerular filtration rate. These alterations were due to a decrease in membrane protein expression of sodium-phosphorus cotransporter and sodium/hydrogen exchanger 3, and the interesting finding is that proteinuria and glycosuria were not observed in these rats. Increased phosphaturia and proximal tubular acidosis may also be biomarkers of TDF-tubular toxicity. Monitoring urine A1M in patients treated with TDF may be a biomarker of tubular toxicity of this antiretroviral drug.
- 5 October 2016
- Published by H1 Connect
Faculty Opinions recommendation of HIV Infection, Tenofovir, and Urine α1-Microglobulin: A Cross-sectional Analysis in the Multicenter AIDS Cohort Study.
In this interesting large cohort study, the authors measured urine α1-microglobulin (A1M) in men with HIV infection and tenofovir disoproxil fumarate (TDF) exposure, mainly with normal kidney function. The results demonstrated that HIV-infected patients presented higher urine A1M levels when compared with HIV-uninfected patients. In HIV-infected patients, higher levels of urine A1M were associated with cumulative TDF use. What was also interesting was the fact that TDF discontinuation was associated with a decrease in A1M levels. These data indicate that urine A1M may be a biomarker of TDF tubular injury. A study from our laboratory {1} demonstrated in rats that low doses of TDF induced tubular nephrotoxicity prior to a decrease in glomerular filtration rate. These alterations were due to a decrease in membrane protein expression of sodium-phosphorus cotransporter and sodium/hydrogen exchanger 3, and the interesting finding is that proteinuria and glycosuria were not observed in these rats. Increased phosphaturia and proximal tubular acidosis may also be biomarkers of TDF-tubular toxicity. Monitoring urine A1M in patients treated with TDF may be a biomarker of tubular toxicity of this antiretroviral drug.
- 29 April 2016
- Published by H1 Connect
Faculty Opinions recommendation of The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
In this interesting experimental study, the authors compared the effects of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin with telmisartan in the progression of chronic kidney disease (CKD) induced in non-diabetic rats by 5/6 nephrectomy (Nx). Four groups of Wistar rats were studied: sham-operated plus placebo; 5/6Nx plus placebo; 5/6 Nx plus linagliptin; and 5/6 Nx plus telmisartan. The results showed that both drugs reduced albumin excretion when compared with the group 5/6 Nx plus placebo. Linagliptin did not lower blood pressure, but it attenuated renal interstitial fibrosis by restoring collagen type I protein expression and also decreased glomerular hypertrophy. In contrast, telmisartan lowered blood pressure, and showed anti-inflammatory and immunomodulatory effects by restoring CD68 renal protein expression and lowering plasma levels of macrophage colony-stimulating factor 1. Another interesting finding was that only telmisartan reduced oxidative stress in this model of CKD. A second study with 5/6 nephrectomy wild-type and genetically deficient DPP-4 rats treated with placebo or linaglipitin confirmed the effective antiproteinuric effect of linaglipitin therapy in both types of rats. It would be interesting to measure inulin clearance, since both drugs did not modify cystatin C levels, and also to look at another group -- Nx plus linagliptin and telmisartan -- in order to verify if this association may increase the beneficial effect on prevention of CKD progression. This beneficial effect of linaglipitin on CKD progression would be interesting to evaluate in clinical studies with nondiabetic patients.
- 29 April 2016
- Published by H1 Connect
Faculty Opinions recommendation of The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy.
In this interesting experimental study, the authors compared the effects of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin with telmisartan in the progression of chronic kidney disease (CKD) induced in non-diabetic rats by 5/6 nephrectomy (Nx). Four groups of Wistar rats were studied: sham-operated plus placebo; 5/6Nx plus placebo; 5/6 Nx plus linagliptin; and 5/6 Nx plus telmisartan. The results showed that both drugs reduced albumin excretion when compared with the group 5/6 Nx plus placebo. Linagliptin did not lower blood pressure, but it attenuated renal interstitial fibrosis by restoring collagen type I protein expression and also decreased glomerular hypertrophy. In contrast, telmisartan lowered blood pressure, and showed anti-inflammatory and immunomodulatory effects by restoring CD68 renal protein expression and lowering plasma levels of macrophage colony-stimulating factor 1. Another interesting finding was that only telmisartan reduced oxidative stress in this model of CKD. A second study with 5/6 nephrectomy wild-type and genetically deficient DPP-4 rats treated with placebo or linaglipitin confirmed the effective antiproteinuric effect of linaglipitin therapy in both types of rats. It would be interesting to measure inulin clearance, since both drugs did not modify cystatin C levels, and also to look at another group -- Nx plus linagliptin and telmisartan -- in order to verify if this association may increase the beneficial effect on prevention of CKD progression. This beneficial effect of linaglipitin on CKD progression would be interesting to evaluate in clinical studies with nondiabetic patients.
- 7 December 2015
- Published by H1 Connect
- Vol. 30 (6)
Faculty Opinions recommendation of Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
OBJECTIVE: To assess if tenofovir (TFV) clearance is associated with urinary retinal-binding protein (RBP) in HIV-positive patients with normal estimated filtration rate. DESIGN: A cross-sectional diagnostic study. METHODS: HIV-positive patients with estimated creatinine clearance above 60 ml/min, on tenofovir disoproxil fumarate (TDF)-containing combination since at least 6 months, taking TDF at night, and without significant comorbidities (diabetes, untreated hypertension, known renal malformations, recurrent nephrolithiasis) and nephrotoxic drugs were included. TFV plasma and urinary concentrations were measured 12 h after drug intake (C12). RBP was measured through enzyme immunoassay kit on spot urines and corrected per urinary creatinine (uRBP/uCr); normality ranges were below 130 μg/g (in patients aged < 50 years) and below 172 μg/g (in patients aged ≥50 years). RESULTS: Two hundred and eighty-nine patients were included (median age of 45.8 years, 71.6% male and 85.4% whites); patients were concomitantly treated with nonnucleoside reverse transcriptase inhibitors (155, 53.6%), protease inhibitors (118, 40.8%), or integrase inhibitors (16, 5.5%)-containing regimens. Estimated creatinine clearance was 89.4 ml/min (78.6-105.9). Urinary RBP (uRBP) and uRBP/uCr were 204.6 ng/ml (92-380) and 169.7 μg/g (85.8-318.3), respectively; abnormally high uRBP/uCr was observed in 157 patients (54.3%). A multivariate binary logistic regression confirmed that both ethnicity (P = 0.004, β 2.93, 95% confidence interval 1.41-6.10) and TFV urinary C12 less than 21 mg/ml (P = 0.006, β 2.04, 95% confidence interval 1.12-3.41) were significantly associated with abnormal uRBP/uCr. CONCLUSION: HIV-positive TDF-treated patients showed a high prevalence of proximal tubular impairment: ethnicity (whites) and low urinary TFV concentrations were significantly associated with elevated uRBP. SDC VIDEO:: http://links.lww.com/QAD/A852.
- 7 December 2015
- Published by H1 Connect
- Vol. 30 (6)
Faculty Opinions recommendation of Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment.
OBJECTIVE: To assess if tenofovir (TFV) clearance is associated with urinary retinal-binding protein (RBP) in HIV-positive patients with normal estimated filtration rate. DESIGN: A cross-sectional diagnostic study. METHODS: HIV-positive patients with estimated creatinine clearance above 60 ml/min, on tenofovir disoproxil fumarate (TDF)-containing combination since at least 6 months, taking TDF at night, and without significant comorbidities (diabetes, untreated hypertension, known renal malformations, recurrent nephrolithiasis) and nephrotoxic drugs were included. TFV plasma and urinary concentrations were measured 12 h after drug intake (C12). RBP was measured through enzyme immunoassay kit on spot urines and corrected per urinary creatinine (uRBP/uCr); normality ranges were below 130 μg/g (in patients aged < 50 years) and below 172 μg/g (in patients aged ≥50 years). RESULTS: Two hundred and eighty-nine patients were included (median age of 45.8 years, 71.6% male and 85.4% whites); patients were concomitantly treated with nonnucleoside reverse transcriptase inhibitors (155, 53.6%), protease inhibitors (118, 40.8%), or integrase inhibitors (16, 5.5%)-containing regimens. Estimated creatinine clearance was 89.4 ml/min (78.6-105.9). Urinary RBP (uRBP) and uRBP/uCr were 204.6 ng/ml (92-380) and 169.7 μg/g (85.8-318.3), respectively; abnormally high uRBP/uCr was observed in 157 patients (54.3%). A multivariate binary logistic regression confirmed that both ethnicity (P = 0.004, β 2.93, 95% confidence interval 1.41-6.10) and TFV urinary C12 less than 21 mg/ml (P = 0.006, β 2.04, 95% confidence interval 1.12-3.41) were significantly associated with abnormal uRBP/uCr. CONCLUSION: HIV-positive TDF-treated patients showed a high prevalence of proximal tubular impairment: ethnicity (whites) and low urinary TFV concentrations were significantly associated with elevated uRBP. SDC VIDEO:: http://links.lww.com/QAD/A852.